Results · Apr-Jun 2026 · filed 5 Aug 2026
Fredun Pharmaceuticals Q1 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 91% to ₹228 crore from ₹119 crore in Apr-Jun 2025.
Operating profit grew 95% to ₹32.2 crore, an operating margin of 14.2% (up 0.3 points from a year ago).
Net profit grew 94% to ₹13.1 crore from ₹6.8 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +8%, net profit +22%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 227.8 | 119.4 | +91% |
| Operating profit (EBITDA) | 32.2 | 16.5 | +95% |
| Operating margin | 14.2% | 13.9% | +0.3 pts |
| Net profit | 13.1 | 6.8 | +94% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 6 quarters
Filings that week
- 8 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 6 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 6 Aug 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
- 6 Aug 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
- 5 Aug 2026Outcome Of The Board Meeting
- 5 Aug 2026Board Meeting Outcome for Outcome Of The Board Meeting
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.